| Part of a series on the |
| COVID-19 pandemic |
|---|
|
| |
The Mu variant (B.1.621) is a variant of SARS-CoV-2. It was first detected in Colombia in January 2021 and was classified by the World Health Organization (WHO) as a variant of interest on August 30, 2021. [1] On March 9, 2022, the organization has de-escalated the Mu variant and its subvariants to previously circulating variants of interest. [2]
With outbreaks of the Mu variant reported in South America and Europe since detection, the WHO said the variant has mutations that indicate a risk of resistance to the current vaccines and stressed that further studies are needed to better understand it. [3] [4] [5] [6]
The B.1.621 lineage has a sublineage, designated B.1.621.1 under the PANGO nomenclature, which has also been detected in multiple countries worldwide. [7]
Within the PANGOLIN naming scheme, the variant was designated as B.1.621. [1] [8] On July 1, 2021, Public Health England (PHE) designated the lineage as a variant under investigation (VUI), calling it VUI-21JUL-1. [9] [10] On August 30, 2021, it was classified as a variant of interest (VOI) by the World Health Organization (WHO) and assigned it the name Mu, following their Greek-letter naming system. The lineage, including its sublineage B.1.621.1, is assigned to Nextstrain clade 21H and GISAID clade GH. [1] On March 9, 2022, the WHO reclassified the Mu variant as a previously circulating VOI as it has been demonstrated to no longer pose a substantially greater risk to global public health compared to other circulating SARS-CoV-2 variants. [2]
The Mu genome has a total number of 21 mutations, including 9 amino acid mutations, all of which are in the virus's spike protein code: T95I, Y144S, Y145N, R346K, E484K or the escape mutation, N501Y, D614G, P681H, and D950N. [8] It has an insertion of one amino acid at position 144/145 of the spike protein, giving a total mutation YY144–145TSN. That mutation is conventionally notated as Y144S and Y145N because insertions would break a lot of comparison tools. It also features a frame-shift deletion of four nucleotides in ORF3a that generates a stop codon two amino acids. The mutation is labeled as V256I, N257Q, and P258*. The list of defining mutations are: S: T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H, and D950N; ORF1a: T1055A, T1538I, T3255I, Q3729R; ORF1b: P314L, P1342S; N: T205I, ORF3a: Q57H, V256I, N257Q, P258*; ORF8: T11K, P38S, S67F. [11] Mutations in viruses are not new. All viruses, including SARS-CoV-2, undergo change over time. Most of these changes are inconsequential, but some can alter properties to make these viruses more virulent or escape the treatment or vaccines. [5]
On August 31, 2021, the WHO released an update which stated that the "Mu variant has a constellation of mutations that indicate potential properties of immune escape," noting that preliminary studies showed some signs of this but that "this needs to be confirmed by further studies." [12]
One such study conducted in a lab in Rome tested the effectiveness of sera collected from recipients of the BioNTech-Pfizer vaccine against the Mu variant, and found that "neutralization of SARS-CoV-2 B.1.621 lineage was robust," albeit at a lower level than that observed against the B.1 variant. [13]
| Gene | Amino acid |
|---|---|
| ORF1a | T1055A |
| T1538I | |
| T3255I | |
| Q3729R | |
| ORF1b | P314L |
| P1342S | |
| S | T95I |
| Y144S | |
| Y145N | |
| R346K | |
| E484K | |
| N501Y | |
| D614G | |
| P681H | |
| D950N | |
| ORF3a | Q57H |
| del257/257 | |
| ORF8 | T11K |
| P38S | |
| S67F | |
| N | T205I |
First identified in Colombia in January 2021, the Mu variant was later categorized as a variant of interest in August 2021. Retrospective analysis revealed that it had already been present in multiple samples collected since late 2020, indicating that it had been circulating since the second wave of the Colombian epidemic. Its prevalence grew rapidly, eventually becoming the dominant strain during the third epidemic wave, highlighting its significant role in the country's COVID-19 epidemiological landscape. [15]
August 6:
August 30:
September 2:
September 3:
September 4:
September 7:
September 8:
September 9:
September 16:
September 18:
| Country | GISAID [39] | outbreak.info [8] | other sources |
|---|---|---|---|
| 5,307 | 6,108 | ||
| 3,972 | 4,974 | ||
| 850 | 958 | ||
| 665 | 690 | ||
| 352 | 447 | ||
| 345 | 435 | ||
| 240 | 276 | 86 [25] | |
| 142 | 162 | ||
| 115 | 118 | ||
| 94 | 94 | ||
| 82 | 85 | ||
| 76 | 76 | 46 [40] | |
| 73 | 74 | ||
| 71 | 67 | 59 [41] | |
| 57 | – | ||
| 51 | 51 | ||
| 49 | 49 | ||
| 48 | 48 | ||
| 41 | 42 | 1 [33] | |
| 41 | 41 | ||
| 33 | 33 | 26 [30] | |
| 29 | 28 | ||
| 20 | 20 | ||
| 20 | 25 | ||
| 19 | 20 | ||
| 17 | 21 | 12 [34] [35] [36] [37] | |
| 16 | 16 | ||
| 15 | 16 | ||
| 15 | 15 | ||
| 11 | 12 | ||
| 10 | 10 | ||
| 8 | 10 | ||
| 8 | 8 | ||
| 5 | 5 | 1 [38] | |
| 5 | 6 | ||
| 5 | 5 | 2 [17] | |
| 5 | – | 1 [27] | |
| 4 | 4 | 4 [24] | |
| 4 | 4 | ||
| 4 | 4 | ||
| 3 | 4 | 2 [19] | |
| 3 | 3 | 3 [22] | |
| 3 | 3 | ||
| 2 | 3 | ||
| 2 | 2 | ||
| 2 | 3 | 5 [29] | |
| 2 | 3 | ||
| 2 | 2 | 2 [28] | |
| 1 | 1 | ||
| 1 | 1 | ||
| 1 | 1 | ||
| 1 | 1 | ||
| 1 | 1 | ||
| 1 | 1 | ||
| 1 | 1 | ||
| 1 | 1 | 3 [23] | |
| 1 | 1 | ||
| – | 1 | ||
| – | – | 6 [21] | |
| – | – | 1 [18] | |
| Total | 12,952 | 15,090 | 260 |